Diagnostics & Genomics
E

Eko Health

Eko Health makes digital stethoscopes and FDA cleared software that analyzes heart sounds and a single lead ECG recorded during a routine exam, for primary care clinicians and health systems that want to find heart disease earlier. The models flag structural heart murmurs in adults and children, atrial fibrillation in adults, and low ejection fraction (40 percent or below) in adults at risk of heart failure. Individual clinicians get murmur and rhythm analysis through the Eko+ membership ($119.99 a year); health systems license SENSORA, which adds low ejection fraction detection on the CORE 500, administration and EHR work, and allows capture by medical assistants and nurses at intake with a clinician overread. The CORE 300, cleared in July 2026 and launched in October 2026 at $249, combines analog and digital listening in one chestpiece and reaches the murmur model through the Eko app.

The software runs in Eko's cloud and works only with Eko hardware, and the company says it has sold more than 750,000 devices. A randomized UK trial across 205 primary care practices (The Lancet, 2026) found no difference in heart failure diagnoses by intention to treat, while use of the device was associated with more detection. The company was founded in 2013 and is based in Emeryville, California.

AI Health Index verifiedNovember 8, 2026
Compare Eko Health with other vendors
Founded
2013
Headquarters
Emeryville, California
Categories
diagnostics-and-genomics, clinical-decision-support
Indexed Products
SENSORA platform, Eko+ membership (murmur and AFib AI), CORE 500 Digital Stethoscope, Eko Low Ejection Fraction Tool, Eko Connect telehealth SDK
Buyer Segments
Large IDN, Community Health System, Independent Practice, Medical Group
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
BB on AI CentralityThe model is the engine of a core module. The platform carries other value, but this capability does not exist without it.
Vendor Published

The AI is the reason a health system buys SENSORA, and the stethoscopes sell without it. Eko's digital stethoscopes offer amplified audio, noise cancellation, waveforms and recording on a free software tier; the cleared models for structural murmur, atrial fibrillation and low ejection fraction come with the paid Eko+ membership for individual clinicians and the SENSORA enterprise license.

SENSORA runs only on Eko hardware (the CORE 500 and the Littmann CORE), and the CORE 300 hybrid stethoscope, launched in October 2026, reaches the murmur model through the Eko app. The models are the engine of the detection product, and the company carries a hardware business underneath that stands without them.

AA on Autonomy and Oversight ModelWhat the system may do and what it may not do are both published, with escalation thresholds, override paths and the conditions that route a case to a person.
Vendor Published

What the software may and may not do is published, with the stop conditions and the human gate. The SENSORA page states that physician or qualified professional review is required for every analysis before clinical use, that the software is not a sole means of diagnosis, and that it does not identify arrhythmias other than atrial fibrillation, so a clear result does not mean a normal rhythm.

The cleared software grades its own inputs: a signal quality classifier withholds murmur analysis on a poor recording, and the rhythm model returns unspecified rhythm or poor ECG signal instead of forcing a call. Murmur results come as high or moderate likelihood, each with a published positive predictive value, and atrial fibrillation detection is limited to adults. Billing the Medicare code requires a documented provider overread, so the review step is tied to payment.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Regulatory Filing

The models and their validation data are described; the update practice is not. The low ejection fraction model is a convolutional neural network over single lead ECG and heart sound (JACC Advances, 2025), and its clearance summary characterizes the training data (1,852 patients from seven US sites and one in India) and the separate test set. The 2025 analysis software is described in its clearance summary as deep neural networks with transformers, with five named components from a signal quality classifier to heart rate calculation, and a head to head comparison with the model it replaced.

Two things are unresolved. The SENSORA page says the low ejection fraction model was trained on more than 100,000 ECG and echocardiogram pairs, which the clearance summary's training description does not match, and nothing reconciles the two. And the software runs in Eko's cloud, where the company describes a newest AI model without a version number, release notes or a statement of when customers are moved to it.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Regulatory Filing

The models are Eko's own and cleared, so the chain is short at the model layer. The analysis software, the low ejection fraction tool and the murmur and rhythm models are Eko products with their own clearances, and the 2025 clearance summary names the storage layer: recordings sit in Eko's cloud on Amazon Web Services S3 and are read by the analysis server.

No subprocessor list is published; the security page says Eko holds business associate agreements with subcontractors and hosting providers without naming them, and the privacy policy mentions third parties that may process data outside the United States.

AA on Clinical and Operational EvidencePeer reviewed or independently evaluated performance, prospective and multi site where the claim requires it, with the method available to read. The grade describes the strength of the evidence, not its direction: a rigorous study that found no benefit grades by its design, and the note leads with what it found.
Peer Reviewed Publication

A randomized trial is published, and on its primary endpoint the tool did not increase detection. TRICORDER (The Lancet, 2026) randomized 205 UK primary care practices; by intention to treat, heart failure diagnoses did not differ between arms after twelve months (incidence rate ratio 0.94, 95 percent CI 0.86 to 1.02). Use of the stethoscope was associated with more heart failure, atrial fibrillation and valve disease diagnoses, and those are the figures on the SENSORA page.

An independent evaluation at Oregon Health and Science University (International Journal of Cardiology, 2025) found the earlier murmur model detected valve disease with 39.3 percent sensitivity and 82.3 percent specificity against echocardiography in 1,029 patients. A prospective primary care study (European Heart Journal Digital Health, 2026) found 92.3 percent sensitivity for moderate or worse valve disease against 46.2 percent for clinicians' own auscultation, with lower specificity. The low ejection fraction model was validated in 2,960 patients at four US networks (JACC Advances, 2025; area under the curve 0.85, positive predictive value 20.3 percent). A randomized trial in Nigeria led by Mayo Clinic (Nature Medicine, 2024) detected more left ventricular dysfunction in pregnancy with an AI enabled digital stethoscope (24 of 587 against 12 of 608). A 2026 veterinary study concerns animals rather than patients.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

The data terms are specific, and they run toward the company. The enterprise terms and conditions give Eko a perpetual, irrevocable, royalty free license to use customer data in de identified or aggregated form for any purpose, naming the development of its algorithms, and assign it all rights in aggregated statistics. The business associate agreement lets Eko de identify any and all protected health information under the HIPAA standard, after which the agreement no longer applies, and the privacy policy says recordings are used to train the algorithms and that anonymized data is kept indefinitely. Identifiable data is kept for the life of an account and up to five years after, and is encrypted at rest.

A heart sound and ECG pair is a physiological signal, and whether removing identifiers from it prevents re identification is not addressed. Eko publishes nothing on safety engineering, meaning guardrails, hallucination mitigation or how a safety event is handled; the nearest thing is a signal quality check that returns a poor signal result rather than a reading.

Regulatory and Compliance
AA on HIPAA and BAA PostureBusiness associate status is stated, the agreement is available to read before contracting, the tier it applies at is clear, and the agreement discloses that it binds subcontractors who handle protected health information. Which parties those subcontractors are is graded on Model Supply Chain Disclosure and is not counted again here. Where any of the four cannot be verified from published material, the grade is the band below.
Vendor Published

The business associate agreement is published and readable before contracting. It applies to any United States customer that is a HIPAA covered entity and takes effect on the customer's acceptance, and it binds Eko to flow down substantially similar restrictions to any subcontractor that receives protected health information; the security page adds that Eko holds such agreements with its subcontractors and hosting providers.

Two terms deserve reading before signing: Eko may de identify any and all protected health information, after which the agreement stops applying, and it may amend the agreement on notice. The agreement does not apply outside the United States, and no equivalent terms are published for the UK, where the company's largest trial ran.

BB on Security Certifications and Trust CenterA recognized certification is named in the vendor own material without the artifact, or with a scope or renewal question the buyer has to raise. A recognized certification here is an audit of how the vendor operates security, such as SOC 2, HITRUST or ISO/IEC 27001. A certification has a scope and a clock, and both are part of this grade. A certification the vendor attaches to its data center, hosting facility or cloud provider, rather than presenting as its own, is the host's and does not count here.
Vendor Published

A recognized attestation is named without the report. The company's security and HIPAA page states that Eko is SOC 2 certified, with no type, period, auditor or report, and describes AES-256 encryption with managed keys, daily encrypted backups and a security contact; the telehealth page repeats SOC 2 compliance. A trust center at trust.ekohealth.com shows nothing until a visitor completes an access request form with name, email, company and reason, so no report can be read before contacting the company.

The device side has outside review: the 2024 and 2025 software clearance summaries record cybersecurity testing as part of FDA review. Nothing says whether the SOC 2 scope covers the cloud that stores recordings.

AA on FDA and Regulatory StatusThe regulatory position is unambiguous and verifiable: a clearance or authorization identifiable in the public databases, with the version and indication it actually covers.
Regulatory Filing

Each model is cleared separately and identifiable in the FDA database. K192004 (January 2020) cleared the original analysis software for murmur and atrial fibrillation in adults; K213794 (June 2022) the structural murmur software for adults and children; K233409 (March 2024) the low ejection fraction tool for adults at risk of heart failure, with Anumana's ECG algorithm as predicate; and K251494 (August 2025) the transformer based analysis software that now covers structural murmur and timing for adults and children and atrial fibrillation for adults. Stethoscope hardware clearances run from 2015 to the CORE 300 (K261694, July 2026), launched in October 2026 for adults and children. The 2025 software clearance carries no predetermined change control plan.

The SENSORA page's description still repeats the 2020 indication wording (adults only, QRS duration and EMAT), so it does not show which clearance covers the software in use.

AA on AI Governance and Bias DisclosureA bias or fairness evaluation with a stated method, subgroup performance, or an independent audit of model behavior. Subgroup performance means published results compared across the groups the product serves, clinical and physiological as well as demographic, so a buyer can see where it underperforms.
Regulatory Filing

Prespecified subgroup results are published for the cleared models, and they show where performance drops. The low ejection fraction clearance summary (K233409) reports results across four age bands, sex, six body mass index bands, race and ethnicity, and conduction disorders: specificity fell to 70.7 percent over age 70 against about 81 percent at 31 to 70, was 73.6 percent in men against 81.8 percent in women, and was lower in patients with pacemakers, atrial fibrillation or wide QRS complexes, with no differences by body mass index or race. The 2025 murmur and rhythm clearance summary (K251494) reports murmur specificity of 76.0 percent in children against 93.9 percent in adults, and no differences by sex or race.

The race comparisons for the murmur and rhythm models rest on validation sets that were 90 and 87 percent White, and results by race are stated as no significant difference rather than shown. An independent evaluation at Oregon Health and Science University (International Journal of Cardiology, 2025) found the earlier murmur model's sensitivity varied widely by valve lesion.

BB on AI Liability and RecourseA published falsifiable commitment, or a real correction route the affected person can exercise against the vendor. A published error rate with its method and denominator grades here. A statutory right that runs to the covered entity rather than to the vendor does not reach this band on its own: every other route here asks something of the vendor, and being located in a particular jurisdiction is not conduct.
Regulatory Filing

Error rates are published with their method and denominators, and nothing in the terms answers for them. The clearance summaries give sensitivity, specificity and predictive values with confidence intervals against echocardiogram or expert reference: 74.7 percent sensitivity and 77.5 percent specificity for low ejection fraction in 3,456 patients, 83.4 and 86.0 percent for structural murmur, and 94.7 and 94.1 percent for atrial fibrillation. A buyer can hold the product to those figures.

The enterprise terms disclaim any warranty that results are accurate, require the customer to indemnify Eko, and cap Eko's liability at three months of fees; the individual terms cap it at $100. The detection guarantee on the website is a refund on the stethoscope, not a commitment on the output.

Integration and Deployment
CC on EHR and Interoperability DepthIntegration is claimed through standards or a middleware layer with no system named and nothing to verify.
Vendor Published

EHR integration is listed as a SENSORA feature with no system named. The plan comparison and the SENSORA page list EHR integration and EHR customization for enterprise customers, and the telehealth product offers SDKs and APIs for streaming into partner video platforms; no record system, marketplace listing, interface standard or reference deployment is named.

The product's Medicare billing needs a documented overread, and nothing published says how results and that review reach the chart.

BB on Deployment Model and Data ResidencyOptions and residency are stated with isolation or the processing path left open.
Vendor Published

Residency is stated, with isolation and the onward path left open. The privacy policy says the services are hosted in the United States, and the 2025 clearance summary describes the analysis software as cloud based, reading recordings from Eko's cloud storage on Amazon Web Services S3 and writing results back. SENSORA licenses are offered in the United States only.

The privacy policy also says data may be processed by third parties in other locations, without naming them, and tenant isolation is not described. There is one deployment option, the hosted cloud, reached through the mobile and desktop apps and an API.

Commercial
BB on Commercial TransparencyA price or a pricing basis is published without full tiers, so a buyer can size the cost before making contact.
Vendor Published

Prices are published for the individual route and withheld for health systems. The plan comparison lists a free Eko Standard tier, Eko+ at $119.99 a year per clinician with murmur and atrial fibrillation detection, and a veterinary tier at $180, all bought online; the CORE 500 stethoscope lists in the store at $449 and the CORE 300 at $249, each with seasonal discounts. SENSORA, which adds low ejection fraction detection, administration, EHR work and on site training, is an annual enterprise license priced through sales.

On the payment side, the company states that CPT code 0962T covers SENSORA analyses and that CMS set outpatient payment under APC 5734 in December 2025, with physician fee schedule coverage varying by carrier; that is payer context rather than what a health system pays.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Peer Reviewed Publication

Coverage is named, with validation behind the primary care use. The clinical scope is cardiac detection: structural murmur for adults and children, atrial fibrillation for adults, and low ejection fraction for adults at risk of heart failure, with capture by medical assistants and nurses at intake. Primary care is validated in the UK trial and the prospective US valve study, and each cleared model has its own validation population.

The company also markets SENSORA for emergency departments, citing one rural hospital, and for telehealth examination, neither with published validation. SENSORA licenses are sold in the United States only. The CORE 300 launch release names emergency departments, pediatric clinics and rural skilled nursing facilities as settings for the stethoscope and its murmur model, and plans a rollout to Canada, the United Kingdom and some European markets.

Tracked Since Listing

Product updates

Material product, regulatory, evidence and commercial changes at Eko Health, each verified against a live source and tagged to the capability axis it bears on. Funding rounds and awards are not product changes and are not logged.

Oct 22, 2026Product / capability

Eko launched CORE 300, an FDA cleared stethoscope whose single chestpiece twists between traditional listening and Cardiac, Pulmonary and All Purpose digital modes, with up to 35 times amplification, active noise cancellation and an on device heart rate display. Connected to the Eko App with an Eko+ membership, it records and visualizes sounds and runs Eko's FDA cleared AI for structural murmur detection. It is on sale in the US now, listed at $249 and currently $199, with Canada, the UK and parts of Europe to follow.

Bears on: FDA and Regulatory StatusSource
Our read on this update →Tracked since Oct 2026
Alternatives

Alternatives to Eko Health

Other products that do the same kind of work as Eko Health, and what each one does.

All Eko Health alternatives, with prices →

AccurKardia makes AccurECG, cloud based software for automated interpretation of ambulatory ECG recordings, sold to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities.

Digital Diagnostics, founded in Coralville, Iowa as IDx Technologies by retina specialist and computer engineer Michael Abramoff, MD, PhD, builds autonomous AI diagnostic systems.

Anumana builds neural network software that reads a standard 12 lead ECG for heart disease the trace does not visibly show, so a health system can find patients earlier from a test it already runs.

Ultromics, a University of Oxford spin out founded in 2017, builds AI that reads a routine echocardiogram and detects disease a reader does not otherwise extract from it, for hospital echocardiography laboratories and cardiology services.

Healthcare information technology company (NASDAQ: HSCS) selling ECG management software to hospitals and practices.

Clarius Mobile Health makes wireless handheld ultrasound scanners and the AI that runs on them.

Comparisons

Compared With

Each comparison carries a written verdict, the buyer conditions that favor each vendor, and a graded side by side. Pairs that cross a category boundary are grouped separately, and their verdicts state where the boundary sits rather than manufacturing a head to head.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
$119.99 per clinician per year (Eko+); SENSORA by quote
$119.99 baseline
Per clinician annual membership for the individual AI tier (Eko+, $119.99 a year, murmur and atrial fibrillation detection), bought online with a stethoscope (CORE 500 at $449 list, CORE 300 at $249). SENSORA, which adds low ejection fraction detection, is an annual enterprise license priced through sales. Published business associate agreement for any US customer that is a HIPAA covered entity, effective on acceptance; not applicable outside the United States. Not published. SENSORA includes on site training and a customer success manager within the license. Vendor Published

Individual pricing is published on the plan comparison page and in the store; SENSORA pricing is not. The company states that CPT code 0962T covers SENSORA analyses and that CMS set outpatient payment under APC 5734 in December 2025, with physician fee schedule coverage varying by carrier and a documented overread required to bill. Reimbursement is payer context, not the price a health system pays.

Eko Health pricing in full →